Evidence map›Paper›PMID 17786239›Full record

ArticleThe Journal of clinical investigation2007

Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers.

Matthew J Potthoff, Hai Wu, Michael A Arnold, John M Shelton, Johannes Backs, John McAnally, James A Richardson, Rhonda Bassel-Duby, Eric N Olson

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 236 papers.

0numbers the graph read from it
0cells of the map it votes in
236citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

236 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Obestatin: canonical and unexpected functions.Reviews in endocrine & metabolic disorders · 2026
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Review
  20. Article

176 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Matthew J PotthoffDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9148, USA.
Hai Wu
Michael A Arnold
John M Shelton
Johannes Backs
John McAnally
James A Richardson
Rhonda Bassel-Duby
Eric N Olson

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skeletal muscle is composed of heterogeneous myofibers with distinctive rates of contraction, metabolic properties, and susceptibility to fatigue. We show that class II histone deacetylase (HDAC) proteins, which function as transcriptional repressors of the myocyte enhancer factor 2 (MEF2) transcription factor, fail to accumulate in the soleus, a slow muscle, compared with fast muscles (e.g., white vastus lateralis). Accordingly, pharmacological blockade of proteasome function specifically increases expression of class II HDAC proteins in the soleus in vivo. Using gain- and loss-of-function approaches in mice, we discovered that class II HDAC proteins suppress the formation of slow twitch, oxidative myofibers through the repression of MEF2 activity. Conversely, expression of a hyperactive form of MEF2 in skeletal muscle of transgenic mice promotes the formation of slow fibers and enhances running endurance, enabling mice to run almost twice the distance of WT littermates. Thus, the selective degradation of class II HDACs in slow skeletal muscle provides a mechanism for enhancing physical performance and resistance to fatigue by augmenting the transcriptional activity of MEF2. These findings provide what we believe are new insights into the molecular basis of skeletal muscle function and have important implications for possible therapeutic interventions into muscular diseases.

Indexed as

AnimalsCell LineDown-RegulationGene Expression Regulation, EnzymologicHistone DeacetylasesIsoenzymesLeupeptinsMEF2 Transcription FactorsMiceMice, KnockoutMuscle Fibers, SkeletalMyogenic Regulatory FactorsOxidation-ReductionPhenotypeProteasome Endopeptidase ComplexProtein Bindingbenzyloxycarbonylleucyl-leucyl-leucine aldehydeHistone DeacetylasesIsoenzymesLeupeptinsMEF2 Transcription FactorsMyogenic Regulatory FactorsProteasome Endopeptidase ComplexUbiquitin

Identifiers

PMID17786239
PMCPMC1957540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.